AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. NOW
4. TXN
5. AMD
6. GOOG
7. INTC
8. CSX
9. KNX
10. IBM

Go back to AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AbbVie (NYSE: ABBV) Delayed: 256.92 +3.62 (1.43%)
Previous Close $253.30    52 Week High $68.12 
Open $253.98    52 Week Low $50.71 
Day High $258.38    P/E 55.73 
Day Low $253.10    EPS $4.61 
Volume 4,410,093